UNSPSC 51432103: Guanclofine

This classification denotes an antihypertensive agent with the molecular formula C9H12CL2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9D89762N7C chemically known as (2-(2,6-dichloroanilino)ethyl)guanidine but generally known as guanclofine, which bears US NIH Compound Identifier 68754. European Medicines Agency schedules Guanclofine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07983MIG.

UNSPSC 51432103 Guanclofine, a Commodity code, covers pharmaceutical products supplied to state and local government healthcare and emergency services operations, specifically emergency life support medications, generic pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and direct procurement channels. State and local governments buying under this code include city fire and rescue departments procuring advanced life support medications for field use, state health and human services commissions establishing pharmacy benefit programs, and multistate cooperative purchasing alliances sourcing generic pharmaceuticals for statewide and interstate distribution across government facilities. Work solicited under the code ranges from direct procurement of specific medication line items (such as epinephrine, labetalol, adenosine, and diltiazem vials for emergency response) to large-scale multi-vendor contracts for generic and OTC product distribution through established pharmaceutical wholesalers, with vendors required to maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act compliance, and appropriate insurance coverage including commercial general liability and professional liability policies.

Recent activity spans Texas, Minnesota, and Florida. The City of Tampa Fire Rescue issued IFB 26P00188 in April 2026 for Advanced Life Support Medications, due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 due March 26, 2026 for Generic Multi Source Pharmaceuticals and OTC Products distributed across multiple state and local government facilities in Minnesota, Oregon, and participating jurisdictions, with evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking market intelligence on direct-to-manufacturer pharmacy prescription programs for state agencies and self-insured employee health plans, reflecting emerging interest in supply-chain models outside traditional pharmacy benefit manager and group purchasing organization channels.